T1	p 54 151	previously untreated advanced breast cancer -- a cancer and leukemia group B study ( CALGB 8642 )
T2	p 540 577	Cancer and Leukemia Group B ( CALGB )
T3	p 585 704	metastatic breast cancer protocol . CALGB 8642 randomizes previously untreated metastatic breast cancer patients either
T4	p 1279 1329	histologically documented measurable breast cancer
T5	p 1358 1372	0-1 . Patients
T6	p 1415 1433	metastatic disease
T7	p 2295 2329	untreated breast cancer patients .
T8	i 6 17	Amonafide :
T9	i 21 27	active
T10	i 154 163	Amonafide
T11	i 193 208	naphthalic acid
T12	i 788 840	standard cyclophosphamide-doxorubicin-5-fluorouracil
T13	i 849 868	immediate treatment
T14	i 874 926	standard cyclophosphamide-doxorubicin-5-fluorouracil
T15	i 1072 1102	precedes standard chemotherapy
T16	i 1451 1463	chemotherapy
T17	i 2252 2261	amonafide
T18	i 2669 2680	phenotyping
T19	o 394 402	toxicity
T20	o 946 951	CALGB
T21	o 988 1030	survival , toxicity , and overall response
T22	o 1504 1521	visceral crisis .
T23	o 1657 1666	reduction
T24	o 1701 1742	hematotoxicity or lack thereof . Toxicity
T25	o 1757 1770	hematological
T26	o 1807 1817	leukopenia
T27	o 1844 1860	thrombocytopenia
T28	o 1875 1885	leukopenia
T29	o 1902 1938	thrombocytopenia . The response rate
T30	o 1964 1997	complete response . When response
T31	o 2014 2036	hematological toxicity
T32	o 2083 2103	leukopenia grade 3/4
T33	o 2176 2202	thrombocytopenia grade 3/4
T34	o 2351 2370	dose-response curve
T35	o 2418 2468	myelosuppression and response . Rates of responses